How to Sell a Medspa in 2026

The medspa M&A market has matured fast. Five years ago, most medical spas were sold by the owner-injector to another nurse practitioner or local dermatologist for 2-3x SDE. Today, aesthetics is one of the hottest PE roll-up sectors in healthcare, and a well-run medspa doing $3M+ in revenue with a diversified injector team can attract multiple platform bids at 7-10x EBITDA.

But the rules for selling a medspa are not the same as selling a dental or veterinary practice. Injector retention, membership program transferability, and medical director compliance can make or break a deal — and most sellers don't even know these are deal issues until buyers start asking questions. Here's how to actually run this process in 2026.

Who's Buying Medspas Right Now

The buyer universe has three distinct tiers, and the multiple you get depends almost entirely on which tier your spa is large enough to attract.

• PE-backed aesthetics platforms — the top of the market. Names like LaserAway (backed by Advent), Ideal Image, Skin Laundry, Sono Bello, Alpha Aesthetics Partners, Skin Spa Group, and regional platforms like SkinSpirit (acquired by LVMH). These buyers want $1M+ EBITDA, multiple locations, and diversified revenue.
• Dermatology and plastic surgery MSOs — firms like Schweiger Dermatology, Forefront Dermatology, and U.S. Dermatology Partners selectively acquire medspas that complement their clinical practices.
• Individual injector-buyers and regional roll-ups — the default pool for single-location medspas under $1M EBITDA. These buyers pay 3-5x SDE, not EBITDA multiples.

The gap between "platform-attractive" and "not platform-attractive" is enormous. A spa at $800K EBITDA might sell for $3M to an individual buyer. The same spa at $1.2M EBITDA with three injectors and a documented membership base might sell for $10M+ to a platform. Understanding where you sit on that line is the first question you should be asking.

Injector Retention Is the Deal

A medspa without its injectors is a lease and some lasers. Buyers know this, and every letter of intent you receive will include injector retention as a closing condition. If you are the primary injector and your nurse practitioner or PA produces less than 30% of injectable revenue, you have a massive concentration problem.

Before going to market, you want:

• At least two employed injectors (NP, PA, or RN depending on state scope) each producing $40K+ per month in injectable revenue.
• Documented employment agreements with non-competes that are enforceable in your state. California, Minnesota, North Dakota, and Oklahoma effectively ban non-competes — in those states, use non-solicits and patient list protections instead.
• Stay bonuses funded from sale proceeds — typically 10-20% of annual comp paid at 18 and 36 months post-close.
• A written training program so buyers see that injector quality is institutional, not personal.

Commission structures matter too. Most medspa injectors work on some variation of 30-40% of collections minus product costs. If your top injector is on an unusual deal (say, 50% plus guaranteed minimum), buyers will flag it as a comp normalization issue and reduce EBITDA accordingly. See our guide on adjusted EBITDA add-backs for how this plays out in diligence.

The Medical Director Compliance Minefield

This is where inexperienced sellers get crushed. Most states require a medspa to operate under the supervision of a licensed physician (MD or DO), and the rules vary wildly:

• Corporate Practice of Medicine (CPOM) states — California, New York, Texas, New Jersey, Illinois — prohibit non-physicians from owning medical practices. Medspas in these states must operate through a professional corporation (PC) owned by a physician, with a management services agreement (MSA) to the non-physician owner's MSO entity.
• Physician supervision requirements — some states require the medical director to be on-site for certain procedures. Others allow remote supervision via telemedicine.
• Good faith exam requirements — most states require a physician or qualified NP/PA to perform an initial consultation before any injectable treatment.

Buyers will have their healthcare regulatory counsel review your structure during diligence, and they will find problems. I have seen deals die the week before close because the medspa was technically operating in violation of state CPOM rules and the buyer's lawyers refused to indemnify around it.

Before going to market, engage a healthcare attorney familiar with your state's rules — firms like ByrdAdatto, Frier Levitt, or Hooper Lundy & Bookman — and get a written compliance opinion. Fix any structural issues 12 months before sale. Restructuring mid-deal is how sellers lose their best bidders.

Membership Programs: Asset or Liability?

Most successful medspas run some version of a membership program — the classic Alle (Allergan) or Aspire (Galderma) loyalty tie-ins, or a proprietary monthly membership at $99-199/month that includes credits, product discounts, and reduced pricing on injectables. These programs drive retention and predictable revenue, which buyers love. But they also create deferred revenue liabilities that buyers will deduct from the purchase price dollar-for-dollar.

If you have 400 members at $149/month with an average credit balance of $300 per member, that's $120,000 of deferred revenue on your balance sheet. The buyer will treat this as debt-like and subtract it from the enterprise value. Sellers who don't track and report this number accurately get ugly surprises during the final purchase price adjustment.

Practical steps: pull a membership liability report from your practice management system (Aesthetic Record, Symplast, PatientNow, Nextech, or Boulevard) monthly for the 12 months before sale. Show the trend. If liabilities are growing faster than collections, you have a structural problem you need to address before marketing.

Revenue Mix and the Laser Trap

The best medspas have roughly this revenue split: 55-70% injectables (Botox/Dysport/Xeomin/Daxxify, Juvederm/Restylane/RHA, Sculptra, Kybella), 15-25% laser and energy devices, 10-15% skincare products, and 5-10% facials/memberships.

Buyers pay the highest multiples for injectable-heavy revenue because it's predictable, high-margin (60-70% gross margin after product cost), and relationship-driven. They discount heavily for laser-dependent revenue because lasers require ongoing capital investment — every 4-6 years you're replacing $150K+ devices. A spa where 50% of revenue comes from a single laser platform (CoolSculpting, Morpheus8, Sofwave, Ultherapy) will get a lower multiple because buyers price in the replacement cycle and the single-vendor risk.

If you have aging lasers, either replace them 18 months before sale (so they're producing returns on the new equipment) or negotiate trade-in pricing with Allergan Aesthetics, Cynosure, Lumenis, or BTL as part of the disclosure schedule.

Data You Need Before Engaging a Banker

Every medspa M&A process starts with a data request list that looks something like this:

• Trailing 36 months of monthly P&Ls, ideally from QuickBooks Online with class tracking by service category.
• Revenue by service line (injectables, lasers, skincare, memberships) by month.
• Revenue by provider by month — this is the injector concentration analysis buyers will run.
• New patient count, returning patient count, and average revenue per visit by month.
• Membership roster with sign-up date, monthly fee, and current credit balance.
• Product inventory aging — Botox and filler have short shelf lives and expired inventory is written off.
• Lease terms and real estate detail.
• Employment agreements, non-competes, and medical director agreement.

If you can't produce this data in 72 hours, you're not ready to sell. Spend 6 months getting your systems clean before you engage a banker. For a broader preparation checklist, see how to prepare your business for sale.

The Bottom Line

The medspa sellers getting premium outcomes in 2026 are the ones who treated their spa like a business for the last three years, not a lifestyle practice. They have real management, documented injector retention, clean compliance structures, and financial reporting that holds up under PE diligence. Everyone else is selling at 3-4x SDE to a local buyer, watching PE platforms pay 8-10x EBITDA for the spa down the street, and wondering what they did wrong. The answer, usually, is that they started thinking about the sale 6 months before going to market instead of 24.